OR WAIT null SECS
The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.
Revolo Biotherapeutics announced the end of a 12 week phase 2a clinical trial evaluating the safety and efficacy of 1104 in patients with eosinophilic esophagitis and other allergies.
In the randomized, double-blind, placebo-controlled, parallel-group study, the investigators 60 patients who received 6 doses of either ‘1104 or placebo over 6 visits within a 12 week period.
The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system.
It is currently being evaluated in a pair of clinical trials for EoE and allergen sensitivity. The company is also exploring other allergic diseases.
Data from the study is expected to release during the second quarter of 2023.
“We are pleased to have reached this relevant milestone and look forward to receiving data from the study in the near future,” said Jonathan Rigby, Chief Executive Officer of Revolo Bio in a statement. “Building on the promising pre-clinical data that has showcased ‘1104’s long-lasting and allergen-agnostic anti-inflammatory effects, we are excited by this clinical progress. We look forward to initiating a food allergy clinical study where there is a very large unmet need as a next step in the development of ‘1104.”